Therapeutic Drug Monitoring ELISA Kits

Therapeutic drug monitoring (TDM) is routinely implemented in inflammatory diseases to improve outcome and reduce treatment costs. TDM provides a means to test the pharmacokinetic (PK) and pharmacodynamic (PD) properties of a drug, providing more robust results in patient monitoring and experimental designs. TDM increases efficacy of response, decreases chance of toxicity and immunogenicity. It also allows for the detection of anti-drug antibodies (ADAs) that can occur with the use of biological therapeutics and hinder drug efficacy. Assay Genie provide a range of ELISA for detection and monitoring of therapeutic drugs and ADAs in serum and plasma samples of any animal for the World’s leading therapeutic antibodies.

These kits use the highest quality components and are manufactured under ISO 13485 quality systems.

Features

• Quantitative ELISA kits for the measurement of the World’s leading therapeutic antibodies & biosimilars
• Qualitative, quantitative & free/total kits enabling full screening of deleterious Anti-Drug Antibodies (ADAs)
• Inter and intra assay CV meet requirements for FDA & EMEA
• Premium quality validated Research-Use-Only ELISA manufactured in Europe under ISO 13485 quality systems
• Validation, verification and lot release performed according to best-in-class scientific guidelines and literature
• Use as little as 10ul sample per well – excellent for clinical, mouse, rat & primate samples
• Get your results in as little as 55 minutes for some kits
• All kits shipped at room temperature

Anti-Cancer

With high mortality and year on year increasing rates, developments of drugs to target different cancers are vital. Current therapeutic antibodies prevent angiogenesis, immune cell evasion and apoptosis inhibition and are used in lung cancer, colon cancer, glioblastomas, solid tumours, breast cancer, colorectal cancer and multiple myeloma.

Checkpoint Inhibitors

Increasing knowledge of how tumours undergo immune evasion has led to the discovery of drugs called checkpoint inhibitors. These immunotherapies can prevent this override of the immune system, and allow the cancer to be detected and destroyed. These biologics are currently used to treat Merkel Cell Carcinoma (MCC), Melanoma, lung cancer, renal cell carcinoma and head and neck cancer.

Anti-Inflammatory

While providing us defence against pathogens, the immune response can also turn inwards and trigger autoimmune disorders. Knowledge of the biochemical pathways involved in inflammation has allowed researchers to target specific agents with therapeutic antibodies/biologics to decrease disease burden, such as arthritis, inflammatory bowel disease, psoriasis, muckle wells disease and many more.

Anti-TNFα

Dysregulation in TNFα signalling is a common occurrence in inflammatory disorders. Thus, a range of therapeutic antibodies have been developed to treat a number of pathologies such as; rheumatoid arthritis, Crohn’s disease, ulcerative colitis and psoriasis. Using TDM for these antibodies during treatment is of great benefit in monitoring patient response, optimising dosage and preventing immunogenicity.

Wet AMD

Macular degeneration is a debilitating illness of the eye that ultimately releases in loss of central vision. Most treatments involve biologics that target VEGF or its receptors to prevent damaging angiogenesis.

Anti-Allergy and Asthma

Incidences of allergy and allergic asthma are on the rise worldwide. Treatments for asthma focus on treating the secondary symptoms. Biologics have been created to bind to free IgE in the treatment of asthmatics who are unresponsive to corticosteroids.

Immune Stimulation

Neutropenia refers to an abnormally low concentration of neutrophils in the blood, and can result in a range of harmful side effects that is commonly seen in patients receiving chemotherapy and HIV. It can be treated with exogenous G-CSF.

Obesity

Biologics have been developed to combat obesity that present with hyperlypidemia to allow LDL to be removed from the blood.

Osteoporosis

With age and hormone changes, alterations occur in bone homeostasis that lead to degeneration of bone cells. By targeting RANK-L, it is possible to prevent the growth of osteoclasts that breakdown bone.

Therapeutic Antibody Monitoring (TDM) ELISA Kits - Key Information

Therapeutic Drug Monitoring ELISA (TDM) Sample Protocol

FAQs

Top 10 Therapeutic Biologic Drugs eBook

In this incredible ebook, we provide a comprehensive review of the Top Selling Biologic Drugs & Biosimilars including their mechanism of action, repurposing and global sales value.